President and chief executive of Genentech Kirk Raab has been fired from his dual post at the head of one of the USA's major biotechnology companies as a result of his disclosure that he had tried to secure a personal loan from Roche, Genentech's majority shareholder, at the time of negotiations with the Swiss company regarding the acquisition of the outstanding shares in Genentech.
The company's board of directors has appointed Genentech's head of research, Arthur Levinson, as Mr Raab's replacement. The company said the change in leadership follows an inquiry by the board.
At a board meeting in June, it was disclosed that during the period of renegotiations with Roche concerning its stake in Genentech, Mr Raab, at his request, discussed with Roche a guarantee by Roche of a $2 million personal bank loan to Mr Raab. No guarantee was provided by Roche.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze